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not prescribed DAPT.
CONCLUSIONS While the majority of TAVR patients in the U.S.
receive DAPT therapy at hospital discharge, antiplatelet prescribing
patterns varied signiﬁcantly among US TAVR hospitals. Outcomes for
DAPT treated patients were generally better than those not treated
with DAPT, but further studies are needed to deﬁne the best antith-
rombotic medical treatment following TAVR.
CATEGORIES STRUCTURAL: Valvular Disease: Aortic
KEYWORDS Antithrombotic therapy, Aortic stenosis, TAVR
TCT-104
Clinical Outcomes of Transcatheter Aortic Valve Replacement for Bicuspid
Aortic Valve Stenosis
Sung-Han Yoon,1 Thierry Lefevre,2 Danny Dvir,3 Jung-Min Ahn,1
Takahide Arai,4 Young-Hak Kim,1 Yusuke Watanabe,5
Paul Hsien-Li Kao,6 Gerald Yong,7 Wei-Hsian Yin,8
Michael Kang-Yin Lee,9 Edgar L. Tay,10 Hyo-Soo Kim,11
Bernard Chevalier,2 Marie-Claude Morice,12 Webb John,13
Seung-Jung Park1
1Asan Medical Center, Seoul, Korea, Republic of; 2ICPS, Massy, France;
3St Paul’s Hospital, Vancouver, Canada, Vancouver, Canada; 4Institut
cardiovasculaire paris sud, Massy, Paris; 5Teikyo university school of
medicine, Tokyo, Japan; 6National Taiwan University Medical School,
Taipai, Taiwan, Taiwan, Republic of China; 7Royal Perth Hospital,
Perth, Western Australia; 8National Yang Ming University, Taipei,
Taiwan, Republic of China; 9Queen Elizabeth Hospital, Kowloon,
China; 10National University Heart Centre, Singapore, Singapore;
11Seoul National University College of Medicine, Seoul, Korea, Republic
of; 12Institut Cardiovasculaire Paris Sud, Générale de Santé, Massy,
France; 13St Pauls Hospital, Vancouver, British Columbia
BACKGROUND Transcatheter aortic valve replacement (TAVR) has
been established as alternative treatment for inoperable or high-risk
patients with symptomatic severe aortic stenosis. However, TAVR for
bicuspid aortic valve stenosis has been still relatively contraindicated
and the clinical data of TAVR for bicuspid aortic valve has been
limited. We sought to evaluate the clinical outcomes of TAVR for
bicuspid aortic valve.
METHODS The Bicuspid TAVR registry was conducted in 9 centers
from 7 countries in Asia, Europe and North America between March
2006 and February 2015. Baseline demographics, procedural and
echocardiographic data were prospectively collected from each center
and a joint database was created.
RESULTS One hundred and thirty-one patients were included. Mean
age was 77.2  9.4 years and 33.6% were female. Medtronic CoreValve,
Edwards SAPIEN/XT and SAPIEN 3 were used in 48.9%, 43.5% and
5.3% of patients, respectively. Approaches were either transarterial
(transfemoral, 78.6%; subclavian, 1.5%; direct aortic, 13.0%) or trans-
apical (6.1%). Mean logistic European System for Cardiac Operative
Risk Evaluation (EuroSCORE) and Society of Thoracic Surgeons (STS)
score were 16.2  12.5 and 5.3  5.1, respectively. At 30 days, the
incidence of all stroke, major vascular complications, life-threateningbleeding, and acute kidney injury (stage 2 or 3) were 1.6%, 4.6%, 4.6%
and 3.8%, respectively. Paravalvular regurgitation moderate or
greater occurred 6.3% in overall, 8.6% in CoreValve, 4.3% in SAPIEN/
XT and 0.0% in SAPIEN 3. Rates of death at 30 days and 1 year were
4.1% and 12.7% for overall, 7.0% and 16.6% for SAPIEN/XT, and 1.6%
and 10.1% for CoreValve, respectively. In multivariate analysis, age
(hazard ratio, 1.17; 95% conﬁdence interval: 1.01 – 1.35; p ¼ 0.038) and
creatinine (hazard ratio, 1.74; 95% conﬁdence interval: 1.05 – 2.89;
p ¼ 0.03) were independent predictors of all-cause death.
Clinical Outcomes of TAVR for Bicuspid Aortic Valve StenosisOverall
(N [ 121)SAPIEN/XT
(N [ 57)CoreValve
(N [ 64) p valueMortality at 30
days5 (4.1%) 4 (7.0%) 1 (1.6%) 0.19Mortality at 1
year14 (12.7%) 8 (16.6%) 6 (10.1%) 0.31All stroke 2 (1.7%) 1 (1.8%) 1 (1.6%) 0.99Life-threatening
bleeding6 (5.0%) 2 (3.5%) 4 (6.3%) 0.68Acute kidney
injury stage 2
to 35 (4.1%) 4 (7.0%) 1 (1.6%) 0.19Major vascular
complication5 (4.1%) 5 (8.8%) 0 (0.0%) 0.02Aortic
regurgitation
moderate or
greater7 (6.7%) 2 (4.3%) 5 (8.6%) 0.08Device success 111 (91.7%) 53 (93.0%) 58 (90.6%) 0.75Safety endpoint
at 30 days98 (81.0%) 42 (73.7%) 56 (87.5%) 0.065CONCLUSIONS This registry reﬂects the real-life experience of TAVR
for bicuspid aortic valve stenosis.
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BACKGROUND Experience with transcatheter aortic valve implanta-
tion (TAVI) for severe aortic regurgitation is limited due to the risk of
insufﬁcient anchoring of the valve stent within the non-calciﬁed
aortic annulus. The aim of this study is to report the initial experience
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ment of pure aortic regurgitation.
METHODS Transapical TAVI with a J-ValveTM system for the treat-
ment of pure aortic regurgitation was performed in
18 patients (Mean age 73.8 3.7 years). All patients were considered
high risk for surgery (Mean logistic Euro-SCORE 24.14.5 %).The
J-ValveTM prosthesis consists of a porcine root valve mounted on a
low-proﬁle self-expanding nitinol stent. This device is featured by
three U-shape anatomically oriented devices -“graspers”, which could
facilitate intuitive ‘self-positioning’ during valve implantation
and provide extra-radial ﬁxation by embracing the native valve leaf-
lets. Procedural results and clinical outcomes up to 30 days were
analyzed.
RESULTS Implantation was successful in 17 of 18 cases (successful
rate 94%), Mean aortic annulus diameter was 25.71.5 mm, six 25mm
and twelve 27mm prosthesis was used. One patient was converted
to open-heart procedure due to valve dislodgment into the ascending
aorta. Mean transvalvular gradient is favorable after
valve implantation (6.91.2mmHg). Post-procedural aortic regurgita-
tion was none/ trace in 15 of 17 and mild in 2 of 17 patients at 30 days
follow-up. No mortality was noted at 30 days follow-up. Pacemaker
implantation for new 3rd AVB was necessary in 2 patients (11%).
CONCLUSIONS Aortic regurgitation remains a challenging pathology
for TAVI. This study revealed the J-ValveTM system is a potential
reasonable option in this subset of patients.
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BACKGROUND Residual aortic regurgitation (AR) following trans-
catheter aortic valve replacement (TAVR) has been reported to be
associated with increased risk of mortality. Quantitation of AR after
TAVR by Doppler-echocardiography remains challenging and cardio-
vascular magnetic resonance (CMR) has been suggested to be more
accurate. However, no data exist on the prognostic value of AR as
assessed by CMR post-TAVR. The objective of this study was therefore
to evaluate the impact of AR as determined by CMR following TAVR
on clinical outcomes.
METHODS 135 patients from 3 centers were included, and AR was
quantitated with the use of regurgitant fraction (RF) measured by
phase-contrast velocity mapping CMR, and using a multi-parametricapproach according to VARC-2 criteria by Doppler-echocardiography.
The median follow-up was 25 [12-41] months and clinical outcomes
included all-cause and cardiac mortality, rehospitalization for heart
failure (HF) and the need for valve prosthesis reintervention.
RESULTS Moderate or severe AR was detected in only 17.1% of the
patients by echocardiography, but 33.1% by CMR, with a modest cor-
relation between both methods (Rs¼0.595; p<0.001). Mean RF by
CMR was 15.7  12.4%, and a higher RF after TAVR was independently
associated with increased risk of all-cause mortality (HR: 1.19 for each
increase of 5% [95% CI of 1.02-1.38]; p¼0.025) and the combined
endpoint of mortality and rehospitalization (HR: 1.21 for each increase
of 5% [95% CI of 1.08-1.35]; p<0.001). A higher RF was also associated
with increased rates of cardiac death, rehospitalization for HF or valve
prosthesis reintervention (HR: 1.20 for each increase of 5% [95% CI of
1.08-1.34]; p¼0.001). Patients with a RF 30% had a combined event
rate of cardiac death, rehospitalization for HF or valve prosthesis
reintervention of 50% at 2-year follow-up (vs. 13% for RF<30%;
p<0.001).
CONCLUSIONS High degrees of CMR-quantiﬁed AR were associated
with increased mortality and poorer clinical outcomes following
TAVR, while echocardiography underestimated AR severity. Quanti-
fying AR by CMR may help to better deﬁne those patients with sig-
niﬁcant residual AR and the eventual need for additional treatment
after TAVR.
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